Amgen’s migraine drug Aimovig continues to impress with its efficacy in late-stage studies.
Amgen‘s migraine drug Aimovig continues to impress with its efficacy in late-stage studies. The company revealed the drug is also effective in reducing the number of episodic headaches in patients who have not responded to previous treatments. Meanwhile, Lilly has published data from its devastating Alzheimer’s flop and Takeda has become the latest drugmaker to fail at tackling the neurodegenerative disease.
Here’s a roundup of these stories and other top clinical news from the past month.
- Amgen Jumps as Migraine Drug Wows in Late-Stage Study
- Merck’s Ace Keytruda Impresses Again, Stuns in Phase III Lung Cancer Trial
- ChemoCentryx Surges on Early-Stage Pancreatic Cancer Trial Data
- Takeda Becomes the Latest to Notch an Alzheimer’s Failure Under Its Belt
- At Last: Eli Lilly Publishes Data for Catastrophic Alzheimer’s Trial
Read More From Karl Thiel:
Get Ready for the M&A Explosion
